David Spellman

Plus aucun poste en cours

Fortune : - $ au 30/04/2024

48 ans

Health Technology

Consumer Services

Anciens postes connus de David Spellman

Sociétés	Poste	Début	Fin
AKEBIA THERAPEUTICS, INC.	Comptroller/Controller/Auditor	30/12/2022	23/06/2023
	Director of Finance/CFO	29/06/2020	23/06/2023
	Treasurer	29/06/2020	23/06/2023
Intarcia Therapeutics, Inc. Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.	Director of Finance/CFO	01/11/2019	29/06/2020
	Corporate Officer/Principal	01/06/2019	01/11/2019
MERSANA THERAPEUTICS, INC.	Director of Finance/CFO	12/03/2018	30/06/2019
VERTEX PHARMACEUTICALS INCORPORATED	Corporate Officer/Principal	-	-

The Wharton School of the University of Pennsylvania

Undergraduate Degree

Internationale

Etats-Unis

Opérationnelle

Director of Finance/CFO	3
Corporate Officer/Principal	2
Undergraduate Degree	1

Sectorielle

Health Technology	5
Consumer Services	2

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés cotées	3
VERTEX PHARMACEUTICALS INCORPORATED	Health Technology
MERSANA THERAPEUTICS, INC.	Health Technology
AKEBIA THERAPEUTICS, INC.	Health Technology

Entreprise privées	1
Intarcia Therapeutics, Inc. Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.	Health Technology

Entreprise privées

Health Technology